Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Peripheral T-Cell Lymphoma (PTCL)”

192 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 192 results

Early research (Phase 1)Active Not RecruitingNCT03240211
What this trial is testing

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Who this might be right for
PTCLCTCL
University of Virginia 37
Testing effectiveness (Phase 2)UnknownNCT05274997
What this trial is testing

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Who this might be right for
Peripheral T/NK Cell Lymphoma (R/R PTCL)
Shanghai YingLi Pharmaceutical Co. Ltd. 97
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Large-scale testing (Phase 3)Active Not RecruitingNCT04668690
What this trial is testing

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Who this might be right for
Peripheral T Cell Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 193
Testing effectiveness (Phase 2)Study completedNCT00787527
What this trial is testing

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 14
Early research (Phase 1)Study completedNCT02594267
What this trial is testing

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL)
Acrotech Biopharma Inc. 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07180771
What this trial is testing

Bosmolisib (BR101801) in Participants With R/R PTCL.

Who this might be right for
Peripheral T Cell Lymphoma
Boryung Pharmaceutical Co., Ltd 44
Testing effectiveness (Phase 2)Ended earlyNCT05883449
What this trial is testing

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma
Affimed GmbH 25
Testing effectiveness (Phase 2)Study completedNCT03052933
What this trial is testing

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Who this might be right for
Mature T-Cell and NK-Cell Neoplasm
Chonnam National University Hospital 28
Testing effectiveness (Phase 2)UnknownNCT02404571
What this trial is testing

GDP in Frontline Chemotherapy for Patients With PTCL-NOS

Who this might be right for
Lymphoma, T-Cell, Peripheral
Chinese Academy of Medical Sciences 28
Testing effectiveness (Phase 2)Looking for participantsNCT06151106
What this trial is testing

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaRefractory T-Cell Lymphoma
The First Affiliated Hospital of Xiamen University 33
Testing effectiveness (Phase 2)Study completedNCT01611142
What this trial is testing

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Lymphoma
Kyowa Kirin Co., Ltd. 38
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
Testing effectiveness (Phase 2)Study completedNCT03372057
What this trial is testing

Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-cell Lymphoma
SecuraBio 156
Testing effectiveness (Phase 2)Ended earlyNCT03947255
What this trial is testing

Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Who this might be right for
Hodgkin LymphomaPeripheral T Cell LymphomaAnaplastic Large Cell Lymphoma
Seagen Inc. 12
Testing effectiveness (Phase 2)Looking for participantsNCT06810778
What this trial is testing

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
T-cell-prolymphocytic LeukemiaCutaneous T-Cell Lymphoma Refractory
Jonsson Comprehensive Cancer Center 12
Testing effectiveness (Phase 2)UnknownNCT02495415
What this trial is testing

Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphoma
CerRx, Inc. 140
Testing effectiveness (Phase 2)WithdrawnNCT03553914
What this trial is testing

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Who this might be right for
Peripheral T Cell Lymphoma
Conjupro Biotherapeutics, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06874946
What this trial is testing

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

Who this might be right for
Precursor T-Cell Lymphoblastic Leukemia-LymphomaT - Cell LymphomaPTCL
Peking University People's Hospital 30
Early research (Phase 1)Looking for participantsNCT07195916
What this trial is testing

Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Who this might be right for
Solid TumorsHematologic Malignancies
Incyte Corporation 280
Next Page